The launch of new therapies and pharmaceuticals, the inclusion of high-priced drugs into the National Health Insurance (NHI) reimbursement system, and the rising healthcare demand driven by population aging have collectively contributed to the steady increase in Taiwan’s total NHI expenditures. Although the government has sought to control overall medical spending through measures such as adjusting premium rates, regulating drug prices under NHI, and implementing new cost-sharing schemes, in recent years, the inclusion of multiple high-priced emerging drugs and medical devices for cancer and rare disease treatments under NHI coverage has further expanded healthcare demand and accelerated the continuous growth of Taiwan’s pharmaceutical market. In 2024, Taiwan’s pharmaceutical market size reached NT$260.31 billion, with a CAGR of 4.4% from 2020 to 2024. Analyzing Taiwan’s pharmaceutical market by therapeutic category in 2024, the top five therapeutic areas were oncology and immunology, gastrointestinal and metabolic, infectious diseases, neurological, and cardiovascular systems. Together, these accounted for approximately 70% of the domestic pharmaceutical market, representing a 5.1% increase compared to 2023.
I、Definition and Scope of the Industry
II、Development of the Pharmaceutical Industry in 2024
III、Key Market Observations
IV、Future Outlook for the Global Pharmaceutical Industry
V、Development Directions and Suggestions for the Pharmaceutical Industry in Taiwan
Table 1 Classification of Pharmaceutical-related Industries in Taiwan